Cart is empty Esophageal adenocarcinoma (EAC), one of two major forms of esophageal cancer, is the sixth most deadly cancer worldwide for which no effective targeted therapy exists. Patients need to rely on chemotherapy as a standard-of-care, which is started ahead of surgical interventions as a so-called “neoadjuvant chemotherapy” (NACT) in the hope of shrinking or controlling tumors. However, most patients become resistant to certain NACTs, leading to poor outcomes.
Leave A Comment